Kidney Transplantation

New study combines Prograf with Rapamune or CellCept

Published in Blood Weekly, October 10th, 2002

Results of a clinical study combining Prograf (tacrolimus)-based immunosuppression with Rapamune (sirolimus) or CellCept (mycophenolate mofetil) were presented at the XIX International Congress of the Transplantation Society in Miami, Florida.

The incidence of biopsy proven acute rejection in patients undergoing kidney transplantation proved to be low in both therapeutic combinations. Additionally, patients assigned to the Prograf-CellCept combination experienced better renal function and exhibited less cardiovascular risk factors including hyperlipidemia and diastolic hypertension.

"Studies such as this that show Prograf can be combined safely with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry